Cefpodoxime proxetil (U-76,252; CS-807) is a new esterified oral cephem antibiotic with a broad antibacterial spectrum. Since data regarding the activity of cefpodoxime against BranhameUa catarrhalis are limited, we tested its activity against 200 B. catarrhalis isolates. The drug was highly active against P-lactamase-negative and -positive isolates; 99% of all strains tested showed a cefpodoxime proxetil MIC of .2.0 ,ug/mI.
ICAAC, abstr. no. 657, 1987) . Since B. catarrhalis has emerged as a major respiratory pathogen (7) and, in fact, is the leading cause of purulent exacerbations of chronic bronchitis at the Mountain Home Veterans Administration Medical Center (unpublished observations), we undertook the present study to Similar to previously reported findings from our facility (1), a total of 160 (80%) of the 200 B. catarrhalis isolates were P-lactamase positive.
In Table 1 , the activity of cefpodoxime proxetil in the form of U-76,253A and eight other oral antibiotics against 40 P-lactamase-negative and 160 ,-lactamase-positive B. catarrhalis isolates is summarized. At a proposed MIC breakpoint of s2.0 p.g/ml, cefpodoxime proved to be highly active against both ,-lactamase-negative and -positive organisms. For only two (1.25%) of the 160 ,B-lactamase-positive group was the cefpodoxime MIC .3.2 ,ug/ml. The eight other antibiotics showed a good level of activity against P-lactamase-negative isolates, with amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole being most active in this group. These latter two agents maintained their high degree of activity even among the P-lactamase-positive isolates.
Others have shown that the ,B-lactamases of B. catarrhalis are highly susceptible to clavulanic acid and that the amoxicillin MICs for 3-lactamase-positive strains can be reduced to values seen among non-enzyme-producing strains by the addition of 0.5 to 1.0 ,ug of clavulanic acid per ml (6, 12). Ampicillin was not reliably active against the 1-lactamaseproducing strains; 18% showed ampicillin MICs of .4.0 ,ug/ ml. Although therapeutic success has been noted with the use of ampicillin in the treatment of ,-lactamase-producing strains of B. catarrhalis, it seems appropriate to avoid the use of ampicillin in this setting (10) . A reevaluation of interpretive criteria used for ampicillin susceptibility testing may further clarify the activity of this drug against various strains of B. catarrhalis (2) . Finally, it should be noted that the MICs for 90% of the ,3-lactamase-producing strains were ANTIMICROB. AGENTS CHEMOTHER. regard, it is acknowledged that j-lactamase instability may not always be reflected by MICs in the resistant range. Overall, our results with antimicrobial agents other than cefpodoxime are consistent with those of Doern and Tubert (5) . With regard to the in vitro activity of cefpodoxime against B. catarrhalis, our data expand considerably upon the findings of Yagi and Zurenko (27th ICAAC) and others (3, 8) , who evaluated small numbers of B. catarrhalis isolates and in certain instances did not clarify the P-lactamase activity associated with the tested strains. The results of the present study confirm a high level of activity of cefpodoxime against both P-lactamase-negative and -positive isolates of B. catarrhalis. Using a proposed MIC breakpoint of s2.0 ,ug/ml, 99% of all tested isolates and 98.8% of j-lactamasepositive isolates were susceptible to cefpodoxime.
In view of the reported in vitro activity of cefpodoxime against Streptococcus pneumoniae and Haemophilus influenzae (both 3-lactamase-negative and -positive isolates) (3, 8) and our data confirming its activity against a substantial number of B. catarrhalis isolates, cefpodoxime may have a role in the treatment of certain respiratory tract infections caused by these pathogens.
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